Drug intelligence / Profile preview

HDT-501

Development stage: Preclinical
Lead developer: HDT Bio
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Small Molecules, mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics

Overview

HDT-501 is a therapeutic mRNA vaccine under development by HDT Bio. It is being investigated primarily for the treatment of neoplasms, with a specific focus on breast cancer. The drug utilizes mRNA technology to stimulate an immune response against tumor cells. As of May 2025, its highest global R&D status is preclinical, and it has not yet entered clinical trials or received regulatory approval. The developer and active organization for this drug is HDT Bio[1][4].

Beyond the preview

Go deeper on HDT-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HDT-501.

Explore the full profile